Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...

Notably contains: Typescript report [probably by Heatley] of the research carried out by Florey, Abraham, Heatley, Page, etc., from Jan 1955 through to Feb 1961, entitled 'Biological Experiments on ...

Ceftobiprole has the potential to be used as monotherapy for the treatment of pneumonia and cSSSIs. Patients with DFIs and osteomyelitis were excluded from the cSSSI clinical trials, and ...

hotmail.com Background Severe bacterial keratitis (BK) typically requires intensive antimicrobial therapy. Empiric therapy is usually with a topical fluoroquinolone or fortified ...